A 2014 Deloitte survey found that 69 percent of chief procurement officers saw cost reduction as their main priority over the following 12 months. In 2018, the same survey showed that the number had jumped to 78 percent.
Imagine yourself at the head of a company that’s on the brink of dizzying growth — a 50-fold increase in employees, and 300 times revenues — within the next three years. Would you be excited or scared?
The measure comes as the London Metal Exchange carries out a supply-chain review to address concerns that cobalt stored in its warehouses may be linked to child labor.
Dozens of lawsuits have been filed against drug makers and sellers over widely prescribed generic heart medications tainted with potential carcinogens.
An independent government report on President Trump’s new North American trade deal estimates it will lead to higher car prices for U.S. consumers and a decline in auto sales.
One of two factories that produces Boeing Co.’s 787 Dreamliner has faced problems with production and oversight that create a safety threat, the New York Times reported.
Pharma companies ramped up their stockpiles of drugs to prepare for a potentially chaotic Brexit. Now they’re in the dark about how long they’ll need to hold them.
